LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

COVID-19 Lung Damage Caused by Persistence of Abnormal Cells

By LabMedica International staff writers
Posted on 19 Nov 2020
Print article
Image: Histological features of COVID-19 lungs (Photo courtesy of the University of Trieste).
Image: Histological features of COVID-19 lungs (Photo courtesy of the University of Trieste).
Several uncertainties still relate to the involvement of other organs in COVID-19. Besides indirect multi-organ injury, a few reports have suggested the possibility of direct injury caused by viral replication in brain, heart and kidney.

Over the last couple of months a few studies have explored the lung pathology caused by COVID-19 infection in a small number of patients. The pattern that has emerged is that COVID-19 lung disease causes diffuse alveolar damage (DAD) which is also present in other conditions of acute respiratory distress syndrome (ARDS), including SARS.

A team of Medical Scientists at the University of Trieste (Trieste, Italy) analyzed the organs of 41 patients who died of COVID-19 at the University Hospital of Trieste. The team took lung, heart, liver, and kidney samples to examine the behavior of the virus. Of the 41 patients, six required intensive care, while 35 were hospitalized in either other hospital units or local nurseries until death. The average age of patients was 77 and 84 years for males and females, respectively. Hypertension, chronic cardiac disease, dementia, diabetes and cancer were the most common comorbidities. All patients eventually died of clinical acute respiratory distress syndrome.

At pathological examination, the investigators found that all cases exhibited lung damage and the lungs appeared congested at macroscopic examination. Meanwhile, histological analysis of all cases revealed gross destruction of the normal lung architecture, consistent with a condition of diffuse alveolar damage with edema, intra-alveolar fibrin deposition with hyaline membranes and hemorrhage. This was accompanied by occlusion of alveolar spaces due to cell delamination. Loss of cellular integrity was also confirmed by the presence of karyorrhexis, indicative of ongoing cellular death.

Further, in situ RNA hybridization for the detection of the SARS-CoV-2 genome indicated that the alterations in the lung were concomitant with persistent viral infection of pneumocytes and endothelial cells. RNA-positive pneumocytes were found to be largely present in the lungs of 10 of 11 tested individuals. The team said presence of abundant cytoplasmic RNA signals and expression of the Spike protein in the lungs after 30-40 days from diagnosis in the study suggests ongoing replication and postulates a continuous pathogenetic role of viral infection.

The scientists also noted that also noted the presence of anomalous epithelial cells among the cases which were characterized by abnormally large cytoplasm and, very commonly, by the presence of bi- of multi-nucleation. Presence of these dysmorphic cells was detected in 87% of patients. They added that the dysmorphic cells very often showed features of syncytia, characterized by several nuclei with an ample cytoplasm surrounded by a single plasma membrane. Most of these syncytia-forming, dysmorphic cells were bona fide pneumocytes.

The authors concluded that COVID-19 is a unique disease characterized by extensive lung thrombosis, long-term persistence of viral RNA in pneumocytes and endothelial cells, along with the presence of infected cell syncytia. Several of COVID-19 features might be consequent to the persistence of virus-infected cells for the duration of the disease. The study was published on November 3, 2020 in the journal EBioMedicine.

Related Links:
University of Trieste

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.